Postmenopausal hormone replacement therapy and cardiovascular disease

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 770-780

  Chae, Claudia U ^a,b   Ridker, Paul M ^a,b   Manson, JoAnn E ^a,c,d  

^a Division of Preventive Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CONJUGATED ESTROGEN; ESTROGEN; FIBRINOGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYPROGESTERONE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; PROGESTERONE; PROSTACYCLIN; PROTEIN C; RALOXIFENE; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HEART PROTECTION; HEMOSTASIS; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; VEIN THROMBOSIS;

EID: 0030839079     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657627     Document Type: Conference Paper

References (181)

1. Heart and Stroke Facts. Dallas, Tex: American Heart Association, 1992.
2. US Senate Special Committee on Aging. Aging America: Trends and Projections. Washington DC: US Dept of Health and Human Services, 1988.
3. Grodstein F and Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women Prog Cardiovasc Diseases 1995;38:199-210.
4. Grady D, Rubin SM, Pettiti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 117: 1016-37.
5. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
6. Falkeborn M, Persson I, Adami H-O, Bergström R, Eaker E, Lithell H, Mohsen R, Naessén T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
7. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35.
8. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
9. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
10. Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA and Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995-2002.
11. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990;75:217-22.
12. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991;87:1274-9.
13. Hanke H, Hanke S, Finking G, Muhic-Lohrer A, Mück AO, Schmahl FW, Haasis R, Hombach V. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits: quantification of cellular proliferation by bromodeoxyuridine. Circulation 1996;94:175-81.
14. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988,115:954-63.
15. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
16. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogens in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1109.
17. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990; 150:2557-62.
18. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995; 38:223-242.
19. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
20. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
21. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7.
22. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-8.
23. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993;15:66-79.
24. Adami H-O, Persson I. Hormone replacement and breast cancer: a remaining controversy? JAMA 1995;274:178-9.
25. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol 1996;87suppl):44S-54S.
26. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993;15:98-107.
27. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens CH, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopasual women. N Engl J Med 1995;332:1589-93.
28. Goldman L and Tosteson ANA. Uncertainty about postmenopausal estrogen: time for action, not debate. N Engl J Med 1991;325:800-2.
29. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and benefits of long-term estrogen replacement therapy: adecision analysis. Obstet Gynecol 1994;83:161-6.
30. Barrett-Connor E. Postmenopausal estrogen use and prevention bias. Ann Intern Med 1991;115:455-6.
31. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
32. Grodstein F. Can selection bias explain the cardiovascular benefits of estrogen replacement therapy? Am J Epidemiol 1996;143:979-82.
33. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary artery disease. New Engl J Med 1989;321:641-6.
34. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: Physiology and Pharmacology. Year Book Medical Publishers, Chicago, IL 1987:187-208.
35. Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259-285.
36. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
37. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987-95.
38. Medical Research Council's General Practice Research Framework. Randomized comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996;312:473-8.
39. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin InterventionsPEPI.Trial. JAMA 1995;273:199-208.
40. Windler EET, Kovanen PT, Chao Y-S, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980;255:10464-10471.
41. Veldhuis JD and Gwynne JT. Estrogen regulates low density lipoprotein metabolism by cultured swine granulosa cells. Endocrinology 1985;117:1321-7.
42. Kushwaha RS and Born KM. Effect of estrogen and progesterone on the hepatic cholesterol 7-alpha-hydoxylase activity in ovariectomized baboons. Biochim et Biophys Acta 1991;1084:300-2.
43. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. Different effects of two progestins on plasma high density lipoproteinHDL2.and postheparin plasma hepatic lipase activity. Atherosclerosis 1981;40:365-369.
44. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: Reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982;54:1113-7.
45. Sacks FM and Walsh BW. The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practice. Ann NY Acad Sci 1990; 592: 272-285.
46. Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A. Lipid metabolic studies in oophorectomised women: effects on serum lipids and lipoproteins of three synthetic progestogens. Maturitas 1982;4:103-11.
47. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apopliprotein A-1. Obstet Gynecol 1991; 77:235-40.
48. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-38.
49. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16.
50. Walsh JME, Grady D. Treatment of hyperlipidemia in women. JAMA 1995;274:1152-8.
51. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989:79;8-15.
52. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332:1758-66.
53. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study4S). Lancet 1994;344:1383-9.
54. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335: 1001-9.
55. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
56. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262-7.
57. Walsh BW, Sacks FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 1993;91:2126-2132.
58. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W for the ARIC Study Group. Plasma lipid, lipoprotein cholesterol, and apoprotein distribution in selected US communities: the Atherosclerosis Risk in Communitie ARIC.Study. Arterioscler Thromb 1993;13:1139-58.
59. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoproteina.levels: the Framingham Offspring Study. Circulation 1993;87:1135-41.
60. Soma MR, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, Crosignani P. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153:1462-68.
61. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lpa.lipoprotein concentrations. Arch Intern Med 1994;154:1106-10.
62. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93.
63. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81.
64. Ridker PM. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. Trends Cadiovasc Med 1995;5:225-9.
65. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
66. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996;276:544-8.
67. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoproteina.and the risk of myocardial infarction. JAMA 1993:270:2195-99.
68. Fortmann SP, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation 1997;95:295-6.
69. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer FJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994;90:1688-95.
70. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K, Wamala SP, Eriksson M, Belkic K, Kirkeeide R, Svane B, Rydén L. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997;95:329-34.
71. Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee YJ, Sakurai H, Yamaguchi H. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women ≥ 55 years of age. Circulation 1996;94:1263-68.
72. Guetta V and Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-37.
73. Barrett-Connor, E and Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
74. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
75. Hough JL and Zilversmit DB. Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 1986;6:57-63.
76. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987;210:37-9.
77. Yagi K, Komura S. Inhibitory effect of female hormones on lipid peroxidation. Biochem Int 1986;13:1051-5.
78. Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA. 17β-estradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophages. Free Radic Res Commun 1990;8:167-73.
79. Mazière C, Auclair M, Ronveaux M-F, Salmon S, Santus R, Mazière J-C. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991;89:175-82.
80. Nègre-Salvayre A, Pieraggi M-T, Mabile L, Salvayre R. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993;99:207-217.
81. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
82. Koh KK, Minemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90.
83. Tracy RP, Bovill EG. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med 1992;116:1307-12.
84. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-66.
85. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principle results of the Northwick Park Heart Study. Lancet 1986:2:533-7.
86. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
87. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-9.
88. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991;83:836-44.
89. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
90. Meade TW, Haines AP, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1983; 1:22-4.
91. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiac risk factors. Atherosclerosis 1991;91:191-205.
92. Lee AJ, Lowe GOD, Smith WCS, Turnstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement herapy. Br J Haematol 1993;83:616-21.
93. Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985;54:475-9.
94. Bonithon-Kopp C, Scarabin P-Y, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Intern J Epidemiol 1990;19:42-8.
95. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445-55.
96. Scarabin P-Y, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemostas 1993;70:584-7.
97. Morrissey JH. Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coag Fibrinol 1995;6:S14-S19.
98. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-44.
99. Hayes TE, Pike J, Tracy RP. Factor VII assays. Arch Pathol Lab Med 1993;117:52-7.
100. Poggio M, Tripodi A, Mariani G, Mannucci PM on behalf of the CISMEL Study Group. Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. Thromb Haemost 1991;65:160-4.
101. Kitchen S, Malia RG, Preston FE. A comparison of methods for the measurement of activated factor VII. Thromb Haemost 1992;68:301-5.
102. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994;71:38-48.
103. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
104. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJ Med 1994;87:403-6.
105. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Münster Heart StudyPROCAM). Isr J Med Sci 1996;32:364-70.
106. Scarabin P-Y, Vissac A-M, Kirzin J-M, Bourgeat P, Amiral J, Agher R, Guize L. Population correlates of coagulation factor VII: importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16:1170-76.
107. Meade TW. Clotting factors and ischaemic heart disease; the epidemiologic evidence. In: Meade TW, ed. Anticoagulants and myocardial infarction: a reappraisal. New York: John Wiley, 1984:91-111.
108. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 199074):77-81.
109. Lindberg UB, Crona L, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis. Thromb haemost 1989;61:65-9.
110. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994:71;420-3.
111. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 1988;111:52-6.
112. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapytransdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate.on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:1-8.
113. Sporrong T, Mattsson L-Å, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Brit J Obstets Gynaecol 1990;97:939-44.
114. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-5.
115. Notelovitz M, Kitchens C, Ware M, Hirschberg K, Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynceol 1983;62:596-600.
116. Notelovitz M, Kitchens CS, Ware MD. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women. Obstet Gynecol;1984:63:621-5.
117. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
118. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
119. Hamsten A, Walldius G, Szamosi A, Blombäck M, de Faire U, Dahlén G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987:2;3-9.
120. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-3.
121. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tarazzi L, Tremoli E, Pozzoli E, Turri M for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993;13:1412-17.
122. Jansson J-H, Olofsson B-O, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993 (part 1); 88:2030-4.
123. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-58.
124. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, Chambless LE, Wu KK for the Atherosclerosis Risk in CommunitiesARIC.Study Investigators. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996;93:1970-5.
125. Mitchell HC. Effect of estrogen and a progestogen on platelet adhesiveness and aggregation in rabbits. J Lab Clin Med 1974;83:79-89.
126. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977; 232:H381-385.
127. Aune B, Øian P, Omsjø I, Østerud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood-A beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol 1995;173:1816-20.
128. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993;81:261-4.
129. Fogelberg M, Vesterqvist O, Diczfalusy U, Henriksson P. Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation. Eur J Clin Invest 1990;20:105-110.
130. Chang W-C, Nakao J, Orimo H, Murota S-I. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activites by estradiol in rat aortic smooth muscle cells. Biochim Biophys Acta 1980;620:472-82.
131. Seillan C, Ody C, Russo-Marie F, Duval D. Differential effects of sex steroids on prostaglandin secretion by male and female cultured piglet endothelial cells. Prostaglandins 1983;26:3-12.
132. David M, Griesmacher A, Müller MM. 17-alpha-ethinylestradiol decreases production and release of prostacyclin in cultured human umbilical vein endothelial cells. Prostaglandins 1989;38:431-8.
133. Witter FR, DiBlasi MC. Effect of steroid hormones on arachidonic acid metabolites of endothelial cells. Obstet Gynecol 1984;63:747-51.
134. Redmond EM, Cherian MN, Wetzel RC. 17β-estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells. Circulation 1994;90:2519-24.
135. Magness RR and Rosenfeld CR. Local and systemic estradiol-17β: effects on uterine and systemic vasodilation. Am J Physiol 1989:256:E536-42.
136. Magness RR, Oarker CR, Rosenfeld CR. Systemic and uterine responses to chronic infusion of estradiol-17β. Am J Physiol 1993; 265:E690-8
137. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-6.
138. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
139. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of endothelium-derived vascular relaxant factor. Nature 1984;308:645-7.
140. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
141. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988:244:19-22
142. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680-7.
143. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-7.
144. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor repsonses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
145. Gilligan DM. Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51.
146. Collins P, Rosano CMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
147. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992;89: 11259-63.
148. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation following acute estrogen withdrawal. Circulation 1994;90:1964-8.
149. Van Buren GA, Yang D, Clark KE. Estrogen-induced uterine vasodilation is anatagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 1992; 167:828-33.
150. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212-6.
151. Roselli M, Imthurn B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/nitrate levels increase with follicular development : indirect evidence for estradiol-mediated NO-release. Biochim Biophys Res Commun 1994;202:1543-1552.
152. Roselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxidenitrite/nitrate.levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995;25(part 2):848-853.
153. Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17β-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994;89:2251-59.
154. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992;263:H271-5.
155. Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Int Med 1993;118:429-32.
156. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
157. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89:1943-50.
158. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper HW. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996;94:1402-7.
159. Rosser M, Chorich L, Howard E, Zamorano P, Mahesh VB. Biol Reprod 1993;48:89-98.
160. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen?: From bedside to bench. Circulation 1995;92:5-8.
161. Hardy SP and Valverde MA. Novel plasma membrane action of estrogen and antiestrogens revealed by their regulation of a large conductance chloride channel. FASEB J 1994;8:760-5.
162. Miller VM and Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1992; 261:R1022-R1027
163. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA. Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-estradiol in vitro. Br J Pharmacol 1991;104:1033-7.
164. Jiang C, Poole-Wilson PA. Sarrel PM, Mochizuki S, Collins P, MacLeod KT. Effect of 17β-oestradiol on contraction, Ca2+.current and intracellular free Ca2+.in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992;106:739-45.
165. Han S-Z, Karaki H, Ouchi Y, Akishita M, Orimo H. 17B-estradiol inhibits Ca2+.influx and Ca2+.release induced by thromboxane A2 in porcine coronary artery. Circulation 1995;91:2619-26.
166. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995;26:807-14.
167. White RE, Darkow DJ, Falvo Lang JL. Estrogen relaxes coronary arteries by opening BKCa.channels through a cGMP-dependent mechanism. Circ Res 1995;77:936-42.
168. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen-a calcium antagonist effect? Lancet 1993;341:1264-5.
169. Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993;109:612-7.
170. Fischer-Dzoga K, Wissler RW, Vesselinovitch D. The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipemic serum. Exp Mol Pathol 1983;39:355-363.
171. Cheng LP, Kuwahara M, Jacobsson J, Foegh ML. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation 1991;52:967-72.
172. Rhee CY, Spaet TH, Stemerman MB, Lajam F, Shiang HH, Caruso E, Litwak RS.
173. Foegh ML, Asotra S, Howell MH, Ramwell PW. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg 1994;19:722-6.
174. Chen S-J, Li H, Durand J, Oparil S, Chen Y-F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-84.
175. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine mdoel. Circulation 1995;91:755-63.
176. Fischer GM, Cherian K, Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis. Atherosclerosis 1981:39:463-7.
177. Fischer GM and Swain ML. Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985;54:1770-85.
178. Beldekas JC, Smith B, Gerstenfeld L, Sonenshein GE, Franzblau C. Effects of 17β-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry 1981:20:2162-7.
179. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
180. Rossouw JE. Estrogens for the prevention of coronary heart disease: putting the brakes on the bandwagon. Circulation 1996;94:2982-5.
181. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995;761;355-60.